References
1) Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965-71.
2) Ness-Jensen E, Lindam A, Lagergren J, et al. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol 2013; 108: 376.
3) Behar J, Sheahan DG, Biancani P, et al. Medical and surgical management of reflux esophagitis. A 38 month report on a prospective clinical trial. N Engl J Med 1975; 293(6): 263–8.
4) Wang YK, Hsu WH, Wang SS, et al. Current pharmacological management of gastroesophageal reflux disease. Gastroenterol Res Pract. 2013; 2013:983653. doi: 10.1155/2013/983653. http://dx.doi.org/10.1155/2013/983653
5) De Ruigh A, Roman S, Chen J, et al. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther 2014; 40(5):531-537. doi:10.1111/apt.12857.
6) Manabe N, Haruma K, Ito M. Takahashi N, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus, 2012; 25(5):373–80.
7) McCarthy DM. Drug therapy: sucralfate. N Engl J Med 1991; 325(14):1017–25.
8) Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; vol. 10, no. 3: 441–6.
9) Ali RAR, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol 2007; 21(5): 793–806.
10) Savarino V, Pace F, Scarpignato C, et al. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease-efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017; 45(5):631-42.
11) Yoshida N, Kamada K, Tomatsuri N et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci 2010; 55: 3393–8.
12) Suzuki T, Matsushima M, Masui A et al. Irsogladine maleate and rabeprazole in non-erosive reflux disease: a double-blind, placebo-controlled study. World J Gastroenterol 2015; 21:5023–31.
13) Kahrilas PJ, Boeckxstaens G: Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? Gut 2012; 61: 1501–9.
14) Zerbib F. Medical treatment of GORD. Emerging therapeutic targets and concepts. Best Pract Res Clin Gastroenterol. 2010; 24(6): 937–46.
15) Alcedo J y Mearin F. La enfermedad por reflujo gastroesofágico y sus complicaciones. En: Montoro Huguet M.A. y García Pagán J.C. Gastroenterología y Hepatología. Problemas comunes en la práctica clínica. 2ª Edición. Madrid, Barcelona: Jarpyo Editores; 2012;197-211.
16) Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2001. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1. Edit: SCM, S.L. 2001; 29-37.
17) Richter JE, Friedenberg FK. Gastroesophageal Reflux Disease. En Sleisenger and Fordtran’s Gastrointestinal and Liver Disease Ninth Edition. 2010; 43: 705-26.
18) Fossmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. Int J Mot Sci 2019, (20): 5203.
19) Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118: S9-31.
20) Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016; 48(8):851-9. doi: 10.1016/j.dld.2016.05.018
21) Arnold J, Brunin I, Riquelme A, et al. Eventos adversos asociados al uso de inhibidores de bomba de protones: un análisis crítico de la evidencia actual. Gastroenterol latinoam 2018; 29(2): 61-8
22) Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009;15(8):990-5.
23) Savarino E, Zentilin P, Frazzoni M, et al. Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterol Motil. 2010; 22(10):1061-e280. doi:10.1111/j.1365-2982.2010.01536.x
24) Weijenborg PW, Cremonini F, Smout AJ, et al. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012; 24(8):747-57, e350. doi: 10.1111/j.1365-2982.2012.01888.x.
25) Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus [published correction appears in Am J Gastroenterol. 2016 Jul;111(7):1077]. Am J Gastroenterol. 2016; 111(1):30-51. doi:10.1038/ajg.2015.322.
26) Wani S, Muthusamy VR, Shaheen NJ, et al. Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Am J Gastroenterol. 2017; 112(7):1032-48. doi:10.1038/ajg.2017.166.
27) Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus. Dig Dis Sci. 2012; 57(10):2625-32. doi:10.1007/s10620-012-2313-2.
28) Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial [published correction appears in Lancet. 2018 Dec 15;392(10164):2552]. Lancet. 2018; 392(10145):400-408. doi:10.1016/S0140-6736(18)31388-6).
29) Sidhwa F, Moore A, Alligood E, Fisichella PM. Diagnosis and Treatment of the Extraesophageal Manifestations of Gastroesophageal Reflux Disease. Ann Surg. 2017;265(1):63-7. doi:10.1097/SLA.0000000000001907.
30) Schindlbeck NE, Klauser AG, Berghammer G et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992; 33: 1016–9.
31) Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106–10.
32) Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther. 2012;35(1):154-64. doi:10.1111/j.1365-2036.2011.04901.x
33) Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease [published correction appears in Am J Gastroenterol. 2013;108(10):1672]. Am J Gastroenterol. 2013;108(3):308-29. doi:10.1038/ajg.2012.444.
34) Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383–91, 1391.e1–e5.
35) Triadafilopoulos G. Stretta: a valuable endoscopic treatment modality for gastro- esophageal reflux disease. World J Gastroenterol. 2014;20(24):7730-38.
36) Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc. 2017;31(12): 4865-82.
37) Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(6):1058-67.e1.
38) Prado Orozco E. Tratamiento endoscópico de la enfermedad por reflujo gastroesofágico (ERGE). En Carlos Arnaud Carreño, Heriberto Medina Franco. Curso precongreso de Cirugía Semana Nacional de Gastroenterología 2018. Hacia una cirugía personalizada. Editado y publicado con la autorización de la Asociación Mexicana de Gastroenterología. AM EDITORES, S.A. Mexico 2018. 27-35. ISBN: 978-607-437-469-8. http://gastro.org.mx/wp-content/uploads/2019/libros/libro-sng-2018-02.pdf
39) Hunter JG, Kahrilas PJ, Bell RCW et al. Efficacy of transoral fundoplication vs. omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterology 2015; 148:324-33 https://doi.org/10.1053/j.gastro.2014.10.009.
40) Trad KS, Barnes WE, Simoni G, et al. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial. Surg Innov 2015; 22: 26-40 [PMID: 24756976 DOI: 10.1177/1553350614526788].
41) Trad KS, Barnes WE, Prevou ER, et al. The TEMPO trial at 5 years: transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surg Innov 2018; 25:149-57.
42) Richter JE, Kumar A, Lipka S et al. Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis. Gastroenterology 2018; 154: 1298-1308.
43) Kim, H.J., Kwon, C., Kessler, W.R. et al. Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device. Surg Endosc 2016; 30: 3402–08.
44) Testoni PA, Mazzoneli G, Distefano G et al. Comparison between Esophyx and MUSE Systems for Transoral Incisionless Fundoplication (TIF) for The Treatment of Gastroesophageal Reflux Disease (GERD): 6 And 12-Month Results from A Single-Center Retrospective Study. Gastrointest Endosc. 2018; Vol. 87, Issue 6, AB252.
45) Inoue H, Ito H, Ikeda H, et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: a pilot study. Ann Gastroenterol. 2014; 27(4):346–51.
46) Inoue H, Tanabe M, Rodríguez de Santiago E et al. Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study. Endosc Int Open 2020; 08(02): E133-E138
47) Wileman SM, McCann S, Grant AM, et al. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 2010; 17(3):CD003243.
48) Engström C, Cai W, Irvine T et al. Twenty years of experience with laparoscopic antireflux surgery. Br J Surg 2012; 99:1415–21.
49) Ferrari D, Asti E, Lazzari V, et al. Six to 12 year outcomes of magnetic sphincter augmentation for gastroesophageal refux disease. Sci Rep. 2020; 10(1):13753. doi: 10.1038/s41598-020-70742-3.
50) Torres Villalobos GM. Nuevas opciones quirúrgicas para el tratamiento de la ERGE: Linx, Endostim. Ecos Internacionales de Cirugía 2019; 125-6.